The FDA said the Covid-19 vaccine from Pfizer met the agency’s criteria for immune responses in a study in children ages 5 to 11 years
The Food and Drug Administration said the Covid-19 vaccine from Pfizer Inc. and BioNTech SE met the agency’s criteria for immune responses in a study in children ages 5 to 11 years.
In a report released Friday, the agency flagged the risk of heart-inflammation conditions including myocarditis associated with the vaccine but said the overall benefits, in preventing Covid-19 disease and hospitalizations, would outweigh the risk of the heart conditions.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Consulte Mais informação »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Consulte Mais informação »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
Consulte Mais informação »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer's study were posted online.
Consulte Mais informação »
Pfizer says COVID-19 vaccine more than 90% effective in kidsPfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children
Consulte Mais informação »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Consulte Mais informação »